Opinion|Videos|January 23, 2025 (Updated: January 23, 2025)
Abiraterone Acetate Versions for Treatment of mCRPC
Author(s)Jose De La Cerda III, MD, MPH
This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?
Advertisement
Related to this article
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5